Not Signed In -
Necrotizing Fasciitis |
|
|
Clinical Trial: Change and Clinical Significance of Plantar Fascia Thickness After ESWT
This study is currently recruiting patients.
Verified by National Taiwan University Hospital June 2005
|
Purpose
The aim of the study is to investigate the effect of extracorporeal shock wave therapy (ESWT) on the thickness of plantar fascia measured by ultrasonographic examination among patients with chronic plantar fascitis. The change of plantar fascia thickness will be corrleted with clinical improvement.
| Condition | Intervention |
|---|---|
| Plantar Fasciitis | Device: Extracorporeal Shock Wave Therapy (Device) |
MedlinePlus related topics: Foot Injuries and Disorders
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Dose Comparison, Parallel Assignment
Official Title: Change and Clinical Significance of Plantar Fascia Thickness After Extracorporeal Shock Wave Therapy
Further Study Details:
Primary Outcomes: Thickness of plantar fascia by ultrasonographic examination at 3 & 6 months
Secondary Outcomes: Pain (visual analogue scale) at 3 & 6 months; Foot function index at 3 & 6 months; Short Form-36 at 3 & 6 months
Expected Total Enrollment: 60
Secondary Outcomes: Pain (visual analogue scale) at 3 & 6 months; Foot function index at 3 & 6 months; Short Form-36 at 3 & 6 months
Expected Total Enrollment: 60
Study start: October 2004; Expected completion: June 2006
Last follow-up: June 2006; Data entry closure: June 2006
The aim of the study is to investigate the effect of extracorporeal shock wave therapy (ESWT) on the thickness of plantar fascia measured by ultrasonographic examination among patients with chronic plantar fascitis. Two different dosage of ESWT will be applied, and the outcome will be followed 3 and 6 months after the treatment. The change of plantar fascia thickness will be corrleted with clinical improvement, including the pain improvement, foot function, and quality of life at follow up.
Eligibility
Ages Eligible for Study: 19 Years and above, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
- diagnosed as plantar fasciitis for at least 6 months
- refractory to other conservative treatments
Exclusion Criteria:
- Acute infection of soft tissue/bone
- Malignancy
- Epiphysiolysis in the focus
- Blood coagulation disorders
- Pregnancy
- Patients with pacemaker
- Foot deformity
- Autoimmune disorders-related arthropahy
- Sciatica
- Previous treatment with ESWT
Location and Contact Information
Please refer to this study by ClinicalTrials.gov identifier NCT00155324
Taiwan
National Taiwan University Hospital, Taipei, 100, Taiwan; Recruiting
H W Liang, MD 886-2-2313456
Study chairs or principal investigators
H W Liang, MD, Principal Investigator, National Taiwan University Hospital
More Information
Study ID Numbers: 9361701153
Last Updated: September 9, 2005
Record first received: September 8, 2005
ClinicalTrials.gov Identifier: NCT00155324
Health Authority: Taiwan: Department of Health
ClinicalTrials.gov processed this record on 2005-09-13
Last Updated: September 9, 2005
Record first received: September 8, 2005
ClinicalTrials.gov Identifier: NCT00155324
Health Authority: Taiwan: Department of Health
ClinicalTrials.gov processed this record on 2005-09-13
Resources
- Necrotizing Fasciitis (Cleveland Clinic)
email this page
print this page
bookmark this page
feedback on this page
